These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321 [TBL] [Abstract][Full Text] [Related]
3. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Marcheselli L; Bari A; Anastasia A; Botto B; Puccini B; Dondi A; Carella AM; Alvarez I; Chiarenza A; Arcari A; Salvi F; Federico M Br J Haematol; 2015 May; 169(4):544-51. PubMed ID: 25817296 [TBL] [Abstract][Full Text] [Related]
4. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206 [TBL] [Abstract][Full Text] [Related]
5. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156 [TBL] [Abstract][Full Text] [Related]
6. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705 [TBL] [Abstract][Full Text] [Related]
7. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. Takahashi H; Tomita N; Sakata S; Tsuyama N; Hashimoto C; Ohshima R; Matsuura S; Ogawa K; Yamamoto W; Kameda Y; Enaka M; Inayama Y; Kasahara M; Takekawa Y; Onoda N; Motomura S; Ishigatsubo Y; Takeuchi K Eur J Haematol; 2013 Apr; 90(4):286-90. PubMed ID: 23331211 [TBL] [Abstract][Full Text] [Related]
9. New treatment options have changed the survival of patients with follicular lymphoma. Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674 [TBL] [Abstract][Full Text] [Related]
10. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574 [TBL] [Abstract][Full Text] [Related]
11. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677 [TBL] [Abstract][Full Text] [Related]
14. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
15. Does monocyte count have prognostic significance in cancer? Tadmor T Leuk Res; 2013 Oct; 37(10):1193-4. PubMed ID: 23953915 [No Abstract] [Full Text] [Related]
17. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP. Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537 [TBL] [Abstract][Full Text] [Related]
19. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479 [TBL] [Abstract][Full Text] [Related]
20. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Taskinen M; Karjalainen-Lindsberg ML; Leppä S Blood; 2008 May; 111(9):4664-7. PubMed ID: 18309035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]